Invention Grant
US08242072B2 Methods of treating inflammation using soluble IL-17RA/RC fusion proteins
有权
使用可溶性IL-17RA / RC融合蛋白治疗炎症的方法
- Patent Title: Methods of treating inflammation using soluble IL-17RA/RC fusion proteins
- Patent Title (中): 使用可溶性IL-17RA / RC融合蛋白治疗炎症的方法
-
Application No.: US13293384Application Date: 2011-11-10
-
Publication No.: US08242072B2Publication Date: 2012-08-14
- Inventor: Steven D. Levin , Mark W. Rixon , Zeren Gao
- Applicant: Steven D. Levin , Mark W. Rixon , Zeren Gao
- Applicant Address: US WA Seattle
- Assignee: ZymoGenetics, Inc.
- Current Assignee: ZymoGenetics, Inc.
- Current Assignee Address: US WA Seattle
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Jill Gorny Sloper, Esq.
- Main IPC: A61K38/00
- IPC: A61K38/00
Abstract:
Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
Public/Granted literature
- US20120082668A1 SOLUBLE IL-17RA/RC FUSION PROTEINS AND RELATED METHODS Public/Granted day:2012-04-05
Information query
IPC分类:
